Pharmacogenomic and Drug Interactions Risk in Cardio-Oncology: A precision medicine perspective for India.
Cardio-oncology patients may face complex treatment regimens due to the concurrent existence of cancer and cardiovascular disease, leading to a considerable polypharmacy burden. This significantly increases the prospect of drug-drug interactions (DDIs) and gene-drug interactions. The majority of these interactions aris...